{"id":"NCT02367040","sponsor":"Bayer","briefTitle":"Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)","officialTitle":"A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-03","primaryCompletion":"2020-08-31","completion":"2024-11-15","firstPosted":"2015-02-20","resultsPosted":"2022-01-04","lastUpdate":"2025-01-17"},"enrollment":458,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma,Non-Hodgkin"],"interventions":[{"type":"DRUG","name":"Copanlisib (Aliqopa, BAY80-6946)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Rituximab","otherNames":[]}],"arms":[{"label":"Copanlisib + Rituximab","type":"EXPERIMENTAL"},{"label":"Placebo + Rituximab","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab and who either had a treatment-free interval of ≥ 12 months after completion of the last rituximab-containing treatment, or who are unwilling to receive chemotherapy/for whom chemotherapy is contraindicated on reason of age, comorbidities, and/or residual toxicity.","primaryOutcome":{"measure":"Progression Free Survival (PFS) Based on Independent Central Review.","timeFrame":"From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years","effectByArm":[{"arm":"Copanlisib + Rituximab","deltaMin":21.5,"sd":null},{"arm":"Placebo + Rituximab","deltaMin":13.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.000002"},{"comp":"OG000 vs OG001","p":"0.000003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":10},"locations":{"siteCount":187,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Chile","China","Colombia","France","Germany","Greece","Hong Kong","Hungary","Ireland","Italy","Japan","Lithuania","Malaysia","Mexico","New Zealand","Philippines","Poland","Portugal","Romania","Russia","Singapore","Slovakia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","Vietnam"]},"refs":{"pmids":["33848462","38226495"],"seeAlso":["http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":161,"n":307},"commonTop":["Hyperglycaemia","Hypertension","Neutrophil count decreased","Diarrhoea","Neutropenia"]}}